Delayed trial readouts

Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.

Summary

521 date moves in Phase 3 and 2/3 studies: 323 later and 198 earlier. The median move later is 183 days.

Date moves

SeenDrugStudyPhaseOld dateNew dateMove
2026-11-20Ferric derisomaltoseNCT05251493Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in PregnancyPhase 32026-12-312026-05-31−214 days
2026-11-19tenofovir alafenamide (Vemlidy), Emtricitabine/tenofovir disoproxil fumarate, Lenacapavir (Sunlenca), BictegravirNCT06544733Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedPhase 2/32028-012026-11-03−424 days
2026-11-19PF-08634404, PembrolizumabNCT06980272SSGJ-707 in Advanced Non-Small Cell Lung CancerPhase 32026-07-302026-02-01−179 days
2026-11-19tilrekimigNCT07839884A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of TimePhase 32034-05-122034-04-21−21 days
2026-11-18INCB123667NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase 32028-11-152027-10-12−400 days
2026-11-18Gemcitabine, AtezolizumabNCT03775265Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerPhase 32027-06-012026-07-23−313 days
2026-11-18DepemokimabNCT07177339eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPhase 32029-04-302029-04-02−28 days
2026-11-18InclisiranNCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesPhase 32027-02-112027-01-16−26 days
2026-11-18TafolecimabNCT07473960IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaPhase 32026-09-062026-08-26−11 days
2026-11-17Daraxonrasib, Nab-paclitaxel, GemcitabineNCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPhase 32028-062028-04−61 days
2026-11-14Oxycodone (Xtampza ER)NCT04659317Opioid-Free OrthopaedicsPhase 32028-122026-07-20−865 days
2026-11-14BGM0504NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExercisePhase 32026-11-142026-08-13−93 days
2026-11-14BGM0504, Semaglutide (Ozempic)NCT06716216A Study of BGM0504 in Participants With Type 2 DiabetesPhase 32026-11-142026-08-25−81 days
2026-11-14maralixibatNCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Phase 32026-102026-07-29−64 days
2026-11-14Bempedoic acidNCT06780410A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic AcidPhase 32025-102025-08-05−57 days
2026-11-13Naloxone (Narcan)NCT03616236Buprenorphine for Probationers and Parolees: Bridging the Gap Into TreatmentPhase 32026-08-312026-01-30−213 days
2026-11-13VosoritideNCT06455059Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaPhase 32026-08-012026-04-23−100 days
2026-11-13barzolvolimabNCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Phase 32026-102026-08-04−58 days
2026-11-13barzolvolimabNCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaPhase 32026-102026-08-12−50 days
2026-11-13BofanglutideNCT06728124A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsPhase 32026-052026-03-26−36 days
2026-11-13Dexamethasone, Elranatamab, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, CarfilzomibNCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)Phase 32026-08-302026-08-26−4 days
2026-11-13setmelanotideNCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayPhase 32025-12-222025-12-19−3 days
2026-11-11PelacarsenNCT05900141An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Phase 32028-08-242026-10-15−679 days
2026-11-11BofanglutideNCT07292441Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossPhase 32027-092026-09-22−344 days
2026-11-11Bofanglutide, Semaglutide (Ozempic)NCT06778967A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusPhase 32026-12-112026-09-18−84 days
2026-11-11Tirzepatide (Zepbound)NCT06162715GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot TrialPhase 2/32027-01-012026-10-10−83 days
2026-11-11Ranibizumab, BevacizumabNCT06952452Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)Phase 32026-072026-05-28−34 days
2026-11-11retatrutideNCT07232719A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightPhase 32027-072027-06−30 days
2026-11-11AfliberceptNCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Phase 32026-102026-09-09−22 days
2026-11-11Cabotegravir/rilpivirine (Cabenuva)NCT07650916A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedPhase 32029-09-042029-08-13−22 days
2026-11-11BofanglutideNCT06777238A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExercisePhase 32026-08-072026-07-30−8 days
2026-11-11metreleptinNCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLPhase 32026-07-212026-07-14−7 days
2026-11-11rilzabrutinibNCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanPhase 32026-11-302026-11-25−5 days
2026-11-10remibrutinibNCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPhase 32031-10-292031-10-15−14 days
2026-11-10Ruxolitinib (Opzelura)NCT06958211Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Phase 32026-10-092026-10-01−8 days
2026-11-10tralokinumabNCT06311682A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic DermatitisPhase 32026-10-202026-10-16−4 days
2026-11-08Rituximab, ObinutuzumabNCT05786768Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic SyndromePhase 2/32027-10-182027-06-30−110 days
2026-11-07TrontinemabNCT07717411A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseasePhase 32032-09-032032-07-30−35 days
2026-11-07Cemdisiran, Pozelimab, Eculizumab, RavulizumabNCT05133531A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentPhase 32026-10-122026-09-28−14 days
2026-11-06Quetiapine (Seroquel), Clozapine, valproate, EsketamineNCT05603104Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment FailurePhase 32028-06-302026-06-24−737 days
2026-11-05CapecitabineNCT05065957Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract CancerPhase 2/32026-072025-07-31−335 days
2026-11-05fluticasone propionateNCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaPhase 32026-11-022026-10-26−7 days
2026-11-04jaktinibNCT05526222A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisPhase 32026-062025-08-05−300 days
2026-11-04Tobevibart (VIR-3434)NCT06903338A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionPhase 32026-12-312026-09-30−92 days
2026-11-03Docetaxel, Gemcitabine, Eribulin mesylate, Sacituzumab GovitecanNCT04579224Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerPhase 32030-08-152026-03-05−1624 days
2026-11-03Entrectinib, Alectinib, DurvalumabNCT05170204A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Phase 32030-06-162027-01-19−1244 days
2026-11-03LanifibranorNCT04849728A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Phase 32027-09-302026-09-29−366 days
2026-11-03DexamethasoneNCT05132920Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhagePhase 32024-122024-09-09−83 days
2026-11-01Nab-paclitaxelNCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic CancerPhase 2/32029-01-152027-12-01−411 days
2026-11-01Docetaxel, Gemcitabine, Risvutatug rezetecanNCT06935409Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailurePhase 32026-08-312026-06-17−75 days
2026-11-01Risvutatug rezetecanNCT06498479ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerPhase 32026-09-302026-08-20−41 days
2026-11-01DocetaxelNCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Phase 32031-06-172031-05-30−18 days
2026-10-31VericiguatNCT05714085Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)Phase 2/32032-04-152029-08-20−969 days
2026-10-31Trastuzumab DeruxtecanNCT07022483A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant SettingPhase 32032-03-232030-02-26−756 days
2026-10-31TadalafilNCT05195775Tadalafil as Adjuvant Therapy for DMDPhase 2/32025-09-052024-04-16−507 days
2026-10-31MethylprednisoloneNCT04163536Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICUPhase 32025-10-252024-11-24−335 days
2026-10-31tocilizumab, MethotrexateNCT03892785MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled TrialPhase 32027-012026-03-27−280 days
2026-10-31Sacituzumab TirumotecanNCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Phase 32027-01-042026-10-19−77 days
2026-10-31RademikibartNCT06488755SIM0718 Treatment of Asthma Clinical StudyPhase 32027-02-282026-12-31−59 days
2026-10-31RanibizumabNCT06957080A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPhase 2/32027-03-012027-01-11−49 days
2026-10-24AficamtenNCT07023341A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyPhase 32026-08-312026-07-14−48 days
2026-10-24pemetrexedNCT04129502TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsPhase 32026-10-312026-09-22−39 days
2026-10-23GemcitabineNCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic CancerPhase 2/32029-01-152027-12-01−411 days
2026-10-23DocetaxelNCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Phase 32027-01-042026-10-19−77 days
2026-10-22Dexamethasone, CT-P44, Lenalidomide, DaratumumabNCT06952478A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple MyelomaPhase 32027-11-152027-03-08−252 days
2026-10-21SHR-1918NCT07349615A Study of SHR-1918 In Participants With HypertriglyceridemiaPhase 32027-112027-03−245 days
2026-10-20MethotrexateNCT05600426A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)Phase 32029-122026-08-06−1213 days
2026-10-20AfliberceptNCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPhase 32028-112027-11−366 days
2026-10-17BenralizumabNCT06750289Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentPhase 32028-11-032026-09-21−774 days
2026-10-17dupilumab, upadacitinibNCT06461897A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisPhase 32030-072029-11−242 days
2026-10-17lamivudine (Epivir-HBV), DolutegravirNCT04022967ANRS 12372 MODERATO StudyPhase 32025-02-052024-12-30−37 days
2026-10-17CenobamateNCT05067634Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresPhase 32026-112026-10-02−30 days
2026-10-17BaxdrostatNCT07007793Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.Phase 32027-08-132027-07-27−17 days
2026-10-16Capecitabine, Fulvestrant, Eribulin mesylate, Alpelisib (BYL719)NCT05063786Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)Phase 32026-062025-12-23−160 days
2026-10-16TelitaciceptNCT06456580A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Phase 32027-052027-03−61 days
2026-10-16Fulvestrant, CapivasertibNCT06764186A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainPhase 32027-12-312027-11-30−31 days
2026-10-16SaruparibNCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Phase 32031-06-172031-05-30−18 days
2026-10-15CapecitabineNCT04495088Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal CancerPhase 32030-082026-07-31−1462 days
2026-10-15Nivolumab, AtezolizumabNCT06646276A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).Phase 32028-04-062027-08-17−233 days
2026-10-15EverolimusNCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentPhase 32027-08-042026-12-30−217 days
2026-10-15IncobotulinumtoxinA (Xeomin)NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigrainePhase 32027-102027-03−214 days
2026-10-15PF-08634404NCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerPhase 2/32032-01-152031-07-22−177 days
2026-10-15Montelukast (Singulair)NCT06113640Montelukast in Parkinson DiseasePhase 2/32026-11-202026-08-20−92 days
2026-10-15Calcipotriene/Betamethasone Dipropionate CreamNCT07357831A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis SubjectsPhase 32026-10-102026-08-06−65 days
2026-10-15Haloperidol, Olanzapine (Zyprexa)NCT07246187Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency DepartmentPhase 32026-10-312026-09-25−36 days
2026-10-15Capecitabine, Datopotamab Deruxtecan, Durvalumab, PembrolizumabNCT05629585A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Phase 32027-09-202027-09-01−19 days
2026-10-15Ruxolitinib (Jakafi), BomedemstatNCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Phase 32027-07-302027-07-14−16 days
2026-10-15OmalizumabNCT07816328Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksPhase 32028-06-022028-05-24−9 days
2026-10-14diazoxide cholineNCT05701774Open-Label Extension Study of DCCR in Patients With Prader-Willi SyndromePhase 32028-062026-01-12−871 days
2026-10-14DocetaxelNCT07821684A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 32031-042030-03−396 days
2026-10-14NivolumabNCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerPhase 2/32032-01-152031-07-22−177 days
2026-10-14Atezolizumab, BevacizumabNCT05482516Evaluating Novel Therapies in ctDNA Positive GI CancersPhase 32026-122026-08-20−103 days
2026-10-14DepemokimabNCT05334368Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialPhase 32027-11-242027-10-29−26 days
2026-10-14remibrutinibNCT07816328Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksPhase 32028-06-022028-05-24−9 days
2026-10-14EsomeprazoleNCT05267613Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.Phase 32026-08-142026-08-10−4 days
2026-10-14ustekinumabNCT05299931An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation StudyPhase 32026-062026-05-29−3 days
2026-10-10pemetrexed, Volrustomig, PembrolizumabNCT05984277A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Phase 32029-02-282026-08-17−926 days
2026-10-10sonelokimabNCT06641076Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugPhase 32027-02-042026-05-28−252 days
2026-10-10sonelokimab, risankizumabNCT06641089Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePhase 32027-01-152027-01-04−11 days
2026-10-09Bevacizumab, AtezolizumabNCT03148418A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Phase 32026-12-312026-11-30−31 days
2026-10-07LecanemabNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseasePhase 32029-06-302026-12-31−912 days
2026-10-07maridebart cafraglutideNCT07225686Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyPhase 32027-09-032027-08-20−14 days
2026-10-07tilrekimigNCT07772921A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe AsthmaPhase 32029-06-122029-06-01−11 days
2026-10-06Telisotuzumab Adizutecan, RamucirumabNCT07821684A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 32031-042030-03−396 days
2026-10-06Calderasib, PembrolizumabNCT06345729A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)Phase 32029-02-192028-01-24−392 days
2026-10-06DepemokimabNCT06961214Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)Phase 32029-08-212028-12-13−251 days
2026-10-06DepemokimabNCT06959095Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationPhase 32029-08-202028-12-13−250 days
2026-10-06EmestedastatNCT06125951Effect of 10 mg Xanamem on Dementia Due to Alzheimer's DiseasePhase 2/32026-102026-09-22−9 days
2026-10-03afimkibartNCT06588855A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative ColitisPhase 32027-01-302026-10-29−93 days
2026-10-03AnifrolumabNCT07691970Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentPhase 32032-12-312032-12-30−1 day
2026-10-02MepolizumabNCT05030155Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)Phase 32025-112025-02-21−253 days
2026-10-01zanubrutinib, RituximabNCT04002297A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationPhase 32027-032026-04-27−308 days
2026-10-01RanibizumabNCT06571045A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPhase 2/32026-09-302026-07-14−78 days
2026-10-01SelinexorNCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaPhase 32026-082026-05-22−71 days
2026-10-01FitusiranNCT03754790Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXPhase 32026-11-052026-09-14−52 days
2026-10-01DapagliflozinNCT06750458Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor PatientsPhase 32026-10-202026-09-20−30 days
2026-09-30maridebart cafraglutideNCT07226765Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyPhase 32027-09-292027-08-30−30 days
2026-09-29Lenacapavir (Sunlenca), BictegravirNCT06532656Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1Phase 2/32030-072026-11−1338 days
2026-09-29Rimegepant (Nurtec ODT)NCT05156398Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsPhase 32031-11-292029-03-27−977 days
2026-09-29Gemcitabine, Rinatabart sesutecan (Rina-S)NCT06619236Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerPhase 32027-022026-08-18−167 days
2026-09-29Palbociclib, Anastrozole, CamizestrantNCT04711252A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseasePhase 32026-08-242026-06-26−59 days
2026-09-29Bevacizumab, PF-08634404NCT07222800Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerPhase 32030-03-292030-02-23−34 days
2026-09-26CangrelorNCT04667078REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEntsPhase 32030-03-012026-12-21−1166 days
2026-09-26TrontinemabNCT07169578A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 32028-06-072028-02-16−112 days
2026-09-26TrontinemabNCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 32028-06-072028-02-16−112 days
2026-09-26Dexamethasone, Bortezomib, Teclistamab, Pomalidomide, DaratumumabNCT05083169A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaPhase 32025-09-152025-08-01−45 days
2026-09-25BenralizumabNCT05692180A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaPhase 32030-05-052026-12-23−1229 days
2026-09-25lunsekimigNCT07793409A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)Phase 32031-10-282031-07-23−97 days
2026-09-25Capecitabine, Zanidatamab, TislelizumabNCT05152147A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersPhase 32026-09-302026-07-15−77 days
2026-09-24Tremelimumab, Bevacizumab, Atezolizumab, Durvalumab, BudigalimabNCT06109272A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Phase 2/32030-092027-01−1339 days
2026-09-24Vicadrostat, EmpagliflozinNCT06531824EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Phase 32028-08-302026-12-31−608 days
2026-09-24Dexamethasone, Etentamig, Lenalidomide, DaratumumabNCT07095452A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantPhase 2/32042-012040-09−487 days
2026-09-24pemetrexed, Rilvegostomig, Datopotamab DeruxtecanNCT06564844A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesPhase 32027-06-302026-07-10−355 days
2026-09-24jaktinibNCT05861102Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)Phase 32026-052025-06-09−326 days
2026-09-24Dexamethasone, Lenalidomide, DaratumumabNCT03993912Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose TherapyPhase 32026-10-072026-08-28−40 days
2026-09-24Tenapanor (Ibsrela)NCT05643534Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsPhase 32026-09-012026-08-20−12 days
2026-09-24BenralizumabNCT07444567Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentPhase 32030-01-032029-12-27−7 days
2026-09-24Tamoxifen (Soltamox)NCT06440967A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyPhase 32026-06-302026-06-25−5 days
2026-09-24LenbelintideNCT07784270A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightPhase 32028-08-092028-08-08−1 day
2026-09-22dupilumabNCT04244006A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton SyndromePhase 2/32024-06-012022-06-01−731 days
2026-09-22DapagliflozinNCT05986136Dapagliflozin in Patients With Ulcerative ColitisPhase 2/32027-08-202026-08-20−365 days
2026-09-22tenofovir alafenamide (Vemlidy), Ulonivirine, Islatravir, BictegravirNCT07266831A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)Phase 2/32029-03-212029-02-01−48 days
2026-09-19maridebart cafraglutideNCT07225686Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyPhase 32027-09-292027-09-03−26 days
2026-09-19ZilebesiranNCT07181109Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseasePhase 32030-09-302030-09-23−7 days
2026-09-17LetrozoleNCT06418347Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile FemalesPhase 32025-11-012025-08-01−92 days
2026-09-17FinerenoneNCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaPhase 32028-10-082028-08-01−68 days
2026-09-15AtezolizumabNCT04543617A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyPhase 32027-03-312026-07-22−252 days
2026-09-15MotixafortideNCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsPhase 32026-12-312026-09-11−111 days
2026-09-15orforglipronNCT06649045A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightPhase 32026-112026-07-21−103 days
2026-09-12Balcinrenone, DapagliflozinNCT06307652Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionPhase 32027-06-112027-04-16−56 days
2026-09-12RavulizumabNCT07557420Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)Phase 32028-10-312028-09-19−42 days
2026-09-12RavulizumabNCT07596784Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)Phase 32027-08-272027-08-17−10 days
2026-09-11ZiltivekimabNCT05636176A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationPhase 32027-07-022026-09-03−302 days
2026-09-11deucravacitinibNCT04036435Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisPhase 32026-07-252026-07-21−4 days
2026-09-10Trastuzumab rezetecan, Docetaxel, PertuzumabNCT06057610A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerPhase 32027-102026-07-15−443 days
2026-09-10Efimosfermin alfaNCT07701993A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)Phase 32033-07-272033-06-23−34 days
2026-09-05DepemokimabNCT05334368Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialPhase 32028-12-192027-11-24−391 days
2026-09-05remibrutinibNCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPhase 32031-10-272031-10-24−3 days
2026-09-04Trastuzumab Emtansine, AtezolizumabNCT04873362A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyPhase 32028-08-312027-03-31−519 days
2026-09-04Riociguat, MacitentanNCT05140525Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPHPhase 32026-12-312026-03-26−280 days
2026-09-04SHR-1819NCT06468956Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisPhase 32026-12-312026-08-26−127 days
2026-09-04Letrozole, InavolisibNCT06790693A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerPhase 32032-05-302032-01-31−120 days
2026-09-04AfliberceptNCT06668064A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Phase 32026-082026-07-13−19 days
2026-09-03PembrolizumabNCT06790966Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPhase 32029-022026-08-25−891 days
2026-09-03RecaticimabNCT07002476Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery OcclusionPhase 32028-06-012027-03-01−458 days
2026-09-03PembrolizumabNCT04534205A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1Phase 2/32029-042028-08−243 days
2026-09-02MethylprednisoloneNCT06496997A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress SyndromePhase 2/32025-082025-04-01−122 days
2026-09-02Rosuvastatin, EnlicitideNCT07216482A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)Phase 32026-08-122026-08-03−9 days
2026-09-01PembrolizumabNCT02954874Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerPhase 32026-08-312026-08-03−28 days
2026-08-29PembrolizumabNCT06422806Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasPhase 32035-06-302032-04-18−1168 days
2026-08-29DurvalumabNCT05211895A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCPhase 32028-07-122026-08-10−702 days
2026-08-29OcrelizumabNCT05999604Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority TrialPhase 32029-112028-05−549 days
2026-08-29TislelizumabNCT04170283A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibPhase 32027-112026-12-31−305 days
2026-08-29GemcitabineNCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAPhase 2/32027-022026-12-01−62 days
2026-08-28elecoglipronNCT07775404A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusPhase 32028-04-202027-06-04−321 days
2026-08-27DepemokimabNCT07671001A Study of Depemokimab in Participants of 6 to 11 Years of AgePhase 32029-03-192027-03-01−749 days
2026-08-27Rosuvastatin, LaroprovstatNCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaPhase 2/32027-02-222025-07-03−599 days
2026-08-27Anrikefon (HSK21542)NCT07186426A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic SurgeryPhase 32026-03-012026-02-24−5 days
2026-08-26InclisiranNCT05030428Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseasePhase 32027-10-132027-05-10−156 days
2026-08-22UblituximabNCT05877963Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 32027-12-012027-01-21−314 days
2026-08-20FinerenoneNCT05196035A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaPhase 32027-05-312027-04-10−51 days
2026-08-20FinerenoneNCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaPhase 32028-11-282028-10-08−51 days
2026-08-20AlectinibNCT06624059A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 32026-08-282026-07-31−28 days
2026-08-17astegolimabNCT05878769A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Phase 32034-07-012027-06-30−2558 days
2026-08-17Entrectinib, CrizotinibNCT04603807A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesPhase 32028-06-262026-09-30−635 days
2026-08-17TapinarofNCT07265479A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisPhase 32028-012027-08−153 days
2026-08-17Dexamethasone, Elranatamab, Pomalidomide, DaratumumabNCT05020236A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsPhase 32026-04-272026-02-26−60 days
2026-08-17Pumitamig, PembrolizumabNCT06712316Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Phase 2/32029-022029-01−31 days
2026-08-17BenralizumabNCT06465485STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic AsthmaPhase 32026-05-292026-05-13−16 days
2026-08-11Bortezomib, SelinexorNCT04939142A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)Phase 32025-12-312024-08-26−492 days
2026-08-11Psilocybin (COMP360)NCT05711940Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDPhase 32026-022025-11-13−80 days
2026-08-08EmpagliflozinNCT07107945A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)Phase 32028-06-262027-04-16−437 days
2026-08-08EnlicitideNCT07216482A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)Phase 32026-12-022026-08-12−112 days
2026-08-08icotrokinraNCT06878404A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisPhase 32026-07-242026-05-25−60 days
2026-08-08Pivekimab Sunirine, Azacitidine, VenetoclaxNCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)Phase 2/32032-062032-05−31 days
2026-08-08Safiglipron (HRS-7535)NCT06904105A Trial of HRS-7535 Tablets in Subjects With Overweight or ObesityPhase 32026-052026-04-17−14 days
2026-08-08mibavademab, metreleptinNCT06548100A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)Phase 32026-07-142026-07-09−5 days
2026-08-05tofacitinibNCT04624230Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative ColitisPhase 32027-04-142027-03-17−28 days

Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.